Skip to main content
Defence Therapeutics Inc. logo

Defence Therapeutics Inc. — Investor Relations & Filings

Ticker · DTC ISIN · CA24463V1013 CSE Manufacturing
Open in API
Filings indexed 195 across all filing types
Latest filing 2024-12-03 Proxy Solicitation & In…
Country CA Canada
Listing CSE DTC

About Defence Therapeutics Inc.

https://defencetherapeutics.com/

Defence Therapeutics Inc. is a biotechnology company focused on developing advanced cancer therapeutics by enhancing drug delivery. Its core technology is the proprietary Accum® platform, a precision intracellular drug-delivery system designed to overcome endosomal entrapment and ensure therapeutic agents reach their cellular targets. Accum® is applied to significantly boost the efficacy and safety of various biologics, including Antibody-Drug Conjugates (ADCs), Radiopharmaceuticals (Radioimmune Conjugates or rADCs), and vaccines. Preclinical models demonstrate that Accum® can increase the potency of enhanced therapies up to 60-fold, enabling safer and more effective first-line treatments. The company utilizes a licensing model for its ADC enhancement technology and actively develops novel radioimmune conjugate assets, aiming to transform existing and next-generation oncology treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a press release concerning delivery of proxy materials (Information Circular) for the upcoming Annual General and Special Meeting (AGSM). It informs shareholders about accessing the proxy statement and voting instructions under Canadian securities laws. This falls under proxy solicitation materials rather than the AGM presentation itself or a results announcement. Therefore, the correct classification is Proxy Solicitation & Information Statement (Code: PSI).
2024-12-03 English
Report of exempt distribution (45-106F1) (amended).pdf
Regulatory Filings Classification · 1% confidence The document is the full text of a completed Canadian securities regulator form (Form 45-106F1 Report of Exempt Distribution) used to report exempt distributions under NI 45-106. This is not a meeting material (AGM-R), earnings release, presentation (IP), or management/annual/interim report. It is not merely an announcement that a report is available, but the actual regulatory filing form. As no specific category matches a Form 45-106 exempt distribution report, it falls into the fallback “Regulatory Filings” category (RNS).
2024-12-02 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing the closing of a non-brokered private placement (issue of units and warrants), amendment to warrant exercise terms, and use of proceeds. This is clearly an update on financing activities and capital structure rather than an earnings release or regulatory filing of a full report. Therefore, it falls under Capital/Financing Update (CAP).
2024-11-30 English
Material change report - English.pdf
Capital/Financing Update Classification · 1% confidence The document is titled “Form 51-102F3 Material Change Report” filed on SEDAR+ and describes the closing of an unsecured convertible debenture offering, the settlement of previous debentures, interest conversions, and related financing terms. This is a detailed update on the company’s fundraising and capital structure change rather than simply an announcement of report publication. It therefore fits the “Capital/Financing Update” category (Code: CAP).
2024-11-29 English
News release - English.pdf
Regulatory Filings
2024-11-23 English
News release - English.pdf
Regulatory Filings
2024-11-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.